ARX 0.93% 54.0¢ aroa biosurgery limited

would not follow Wilson advice at all. Brokers are too bias...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 455 Posts.
    lightbulb Created with Sketch. 177
    would not follow Wilson advice at all. Brokers are too bias depending on stocks they float or raise for. Starting to think I will not follow any broker advice anymore. The stocks are in same space but one is biologic and one synthetic. Gives treating doctors point of difference. Both I feel will prosper. I have been in PNV for over 10 years. I wish you all well. But to say one is obviously much better either clinically or as a company is just wrong. Both will do well long term. PNV will continue to grow as it covers an aspect of the market burns surgeons are asking for and increasingly using; synthetics.
    bill
 
watchlist Created with Sketch. Add ARX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.